To rule out possible off-target effects of EZH2 pharmacological inhibitors and gain some meaningful insights into the downstream signaling pathways governed by EZH2, high-throughput RNA sequencing, and quantitative proteomics were performed in four different PAH-PASMCs cell lines subjected to EZH2 silencing using siRNA. This evidence concerns the gene EZH2 and pulmonary arterial hypertension.